Page 99 - 《中国药房》2025年7期
P. 99
and treatment[J]. Lancet，2020，396（10246）：277-287. and carboplatin combination chemotherapy in a hemo-
[ 3 ] MAGEE C. Kidney disease and death from cancer[J]. Am dialysis patient with advanced ovarian cancer[J]. Gynecol
J Kidney Dis，2014，63（1）：7-9. Oncol，2002，84（2）：335-338.
[ 4 ] US Food and Drug Administration. Pharmacokinetics in [15] WOO M H，GREGORNIK D，SHEARER P D，et al. Phar‐
patients with impaired renal function：study design，data macokinetics of paclitaxel in an anephric patient[J]. Can‐
analysis，and impact on dosing and labeling[EB/OL]. cer Chemother Pharmacol，1999，43（1）：92-96.
[2024-08-31]. https：//www.fda.gov/media/78573/down‐ [16] LI Y F，FU S，HU W，et al. Systemic anticancer therapy in
load. gynecological cancer patients with renal dysfunction[J].
[ 5 ] MODI G，MADABHAVI I，PATEL A，et al. Treatment of Int J Gynecol Cancer，2007，17（4）：739-763.
breast cancer in a patient of Alport syndrome-induced [17] MICALLEF R A，BARRETT-LEE P J，DONOVAN K，
chronic renal failure：a triumph story[J]. J Cancer Res et al. Trastuzumab in patients on heamodialysis for renal
Ther，2018，14（2）：462-464. failure[J]. Clin Oncol （R Coll Radiol），2007，19（7）：559.
[ 6 ] CAI J H，ZHENG J H，LIN X Q，et al. Individualized [18] MCKEAGE K，PERRY C M. Trastuzumab：a review of its
treatment of breast cancer with chronic renal failure：a use in the treatment of metastatic breast cancer over-
case report and review of literature[J]. World J Clin Cases， expressing HER2[J]. Drugs，2002，62（1）：209-243.
2021，9（33）：10345-10354. [19] GIANNI L，PIENKOWSKI T，IM Y H，et al. 5-year analy‐
[ 7 ] GRADISHAR W J，ANDERSON B O，ABRAHAM J，et sis of neoadjuvant pertuzumab and trastuzumab in patients
al. Breast cancer，version 3，2020，NCCN clinical practice with locally advanced，inflammatory，or early-stage
guidelines in oncology[J]. J Natl Compr Canc Netw， HER2-positive breast cancer （NEOSPHERE）：a multi-
2020，18（4）：452-478. centre，open-label，phase 2 randomized trial[J]. Lancet
[ 8 ] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会 Oncol，2016，17（6）：791-800.
（CSCO）乳腺癌诊疗指南：2022[M]. 北京：人民卫生出版 [20] SHAO Z M，PANG D，YANG H J，et al. Efficacy，safety，
社，2022：25-30. and tolerability of pertuzumab， trastuzumab， and
[ 9 ] OZOLS R F，BUNDY B N，GREER B E，et al. Phase Ⅲ docetaxel for patients with early or locally advanced
trial of carboplatin and paclitaxel compared with cisplatin ERBB2-positive breast cancer in Asia：the PEONY phase
and paclitaxel in patients with optimally resected stage Ⅲ 3 randomized clinical trial[J]. JAMA Oncol，2020，6（3）：
ovarian cancer：a Gynecologic Oncology Group study[J]. e193692.
J Clin Oncol，2003，21（17）：3194-3200. [21] QUARTINO A L，LI H B，JIN J Y，et al. Pharmacokinetic
[10] CALVERT A H，NEWELL D R，GUMBRELL L A，et al. and exposure-response analyses of pertuzumab in combi‐
Carboplatin dosage：prospective evaluation of a simple nation with trastuzumab and docetaxel during neoadjuvant
formula based on renal function[J]. J Clin Oncol，1989，7 treatment of HER2+ early breast cancer[J]. Cancer Che‐
（11）：1748-1756. mother Pharmacol，2017，79（2）：353-361.
[11] EGORIN M J，VAN ECHO D A，TIPPING S J，et al. Phar‐ [22] KEIZER R J，HUITEMA A D R，SCHELLENS J H M，
macokinetics and dosage reduction of cis-diammine（1，1- et al. Clinical pharmacokinetics of therapeutic monoclonal
cyclobutane dicarboxylato）-platinum in patients with im‐ antibodies[J]. Clin Pharmacokinet，2010，49（8）：493-507.
paired renal function[J]. Cancer Res，1984，44（11）：5432- [23] HERRSTEDT J，ROILA F，WARR D，et al. 2016 updated
5438. MASCC/ESMO consensus recommendations：prevention
[12] LONGNECKER S M，DONEHOWER R C，CATES A E， of nausea and vomiting following high emetic risk chemo‐
et al. High-performance liquid chromatographic assay for therapy[J]. Support Care Cancer，2017，25（1）：277-288.
taxol in human plasma and urine and pharmacokinetics in [24] GRIFFITHS E A，ROY V，ALWAN L，et al. NCCN guide‐
a phase Ⅰ trial[J]. Cancer Treat Rep，1987，71（1）：53-59. lines insights：hematopoietic growth factors，version 1，
®
[13] TOMITA M，KURATA H，AOKI Y，et al. Pharmacokine- 2022[J]. J Natl Compr Cancer Netw，2022，20（5）：
tics of paclitaxel and cisplatin in a hemodialysis patient 436-442.
with recurrent ovarian cancer[J]. Anticancer Drugs，2001， （收稿日期：2024-09-04 修回日期：2025-02-04）
12（5）：485-487. （编辑：张元媛）
[14] WATANABE M，AOKI Y，TOMITA M，et al. Paclitaxel
中国药房 2025年第36卷第7期 China Pharmacy 2025 Vol. 36 No. 7 · 857 ·
